A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to determine the maximum tolerated dose of niraparib when
combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer.
Once this is determined, this dose will be tested to identify what impact it has on the tumor
as well as patient reported outcome measures.